Pfizer Inc, has released promising top-line data for its Abrysvo vaccine, demonstrating high efficacy against respiratory syncytial virus (RSV) in adults aged 60 and older. These findings from the Phase 3 clinical trial hold significant implications for infection control personnel working to combat RSV infections, especially in vulnerable populations.